Artelo Biosciences (ARTL) Cash from Investing Activities (2017 - 2025)
Artelo Biosciences (ARTL) posted quarterly Cash from Investing Activities of $188000.0 for Q4 2025, down 62.4% year-over-year from $500000.0 in Q4 2024, and up 175.2% quarter-over-quarter from -$250000.0 in Q3 2025.
Artelo Biosciences (ARTL) Cash from Investing Activities (2017 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Cash from Investing Activities for 9 consecutive years, with $188000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Investing Activities fell 62.4% year-over-year to $188000.0; the TTM figure through Dec 2025 stood at -$62000.0 (down 100.8% YoY), while the FY2025 annual figure was -$62000.0, down 100.8% from the prior year.
- Cash from Investing Activities grew to $188000.0 in Q4 2025 per ARTL's latest filing, from -$250000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $4.2 million in Q3 2024 and bottomed at -$8.9 million in Q4 2021.
- Historically, Cash from Investing Activities has averaged $298956.6 across 5 years, with a median of $449500.0 in 2023.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 755.64% — and 2025, when it plunged 105.88%.
- Artelo Biosciences' Cash from Investing Activities stood at -$8.9 million in 2021, then jumped by 120.23% to $1.8 million in 2022, then soared by 52.62% to $2.7 million in 2023, then tumbled by 81.76% to $500000.0 in 2024, then slumped by 62.4% to $188000.0 in 2025.
- Business Quant data shows ARTL's Cash from Investing Activities at $188000.0 in Q4 2025, -$250000.0 in Q3 2025, and $500000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Artelo Biosciences | 107,735.40 | -492,264.60 | - | 188,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 188,000.00 |
| Dec 31, 2025 | 188,000.00 |
| Sep 30, 2025 | -250,000.00 |
| Sep 30, 2025 | -250,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | 4.25 Mn |
| Sep 30, 2024 | 4.25 Mn |
| Jun 30, 2024 | 1.75 Mn |
| Jun 30, 2024 | 1.75 Mn |
| Mar 31, 2024 | 1.27 Mn |
| Mar 31, 2024 | 1.27 Mn |
| Dec 31, 2023 | 2.74 Mn |
| Dec 31, 2023 | 2.74 Mn |
| Sep 30, 2023 | -1.83 Mn |
| Sep 30, 2023 | -1.83 Mn |
| Jun 30, 2023 | 399,000.00 |
| Jun 30, 2023 | 399,000.00 |
| Mar 31, 2023 | 2.20 Mn |
| Mar 31, 2023 | 2.20 Mn |